Isis on a roll as it signs another licence deal
05:51 EST 12 Dec 2012 | thePharmaLetter
With the ink barely dry on its $630 million deal with Biogen Idec (The Pharma Letter December 11),antisense specialist Isis Therapeutics has signed an agreement with AstraZeneca to develop fivecancer drugs. Under the terms of the deal, Isis and Astra..
Original Article: Isis on a roll as it signs another licence deal
More From BioPortfolio on "Isis on a roll as it signs another licence deal"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
